CLINICAL TRIAL

Questionnaire Administration for Lung Cancer

Stage I
Waitlist Available · 18+ · All Sexes · Buffalo, NY

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

See full description

About the trial for Lung Cancer

Eligible Conditions
Lung Neoplasms · Stage IA3 Lung Cancer AJCC v8 · Stage IIA Lung Cancer AJCC v8 · Non-Small Cell Lung Carcinoma (NSCLC) · Carcinoma, Non-Small-Cell Lung · Stage IB Lung Cancer AJCC v8 · Stage IA2 Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8 · Stage I Lung Cancer AJCC v8 · Stage II Lung Cancer AJCC v8 · Stage IIB Lung Cancer AJCC v8

Treatment Groups

This trial involves 2 different treatments. Questionnaire Administration is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Questionnaire Administration
OTHER
Informational Intervention
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Best Practice
OTHER
Questionnaire Administration
OTHER

Eligibility

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age >= 18 years of age
You have biopsy-proven stage I-II non-small cell lung cancer (NSCLC). show original
Eligible for both surgery and SBRT
Able to provide informed consent in English
Have verbal fluency in English
You must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: At 6 months
Screening: ~3 weeks
Treatment: Varies
Reporting: At 6 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: At 6 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Questionnaire Administration will improve 1 primary outcome and 3 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 6 months.

Difference in consideration of regret
UP TO 6 MONTHS
Compare decisions about treatment for early stage lung cancer and examined whether regret is a consideration in treatment decisions between those who received the quality of life fact sheet and those who did not.
UP TO 6 MONTHS
Quality of Life (EORTC QLQ-C30)
UP TO 6 MONTHS
Will compare QOL measures based on the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) between the provision of QOL information versus usual care for standard of care surgery or SBRT treatment.
UP TO 6 MONTHS
Quality of Life (QOL)
UP TO 6 MONTHS
Will compare QOL measures based on the lung cancer- specific questionnaire (EORTC QLQ-LC13) between the provision of QOL information versus usual care for standard of care surgery or SBRT treatment.
UP TO 6 MONTHS
Decision regret
AT 6 MONTHS
Compare the extent of decision regret based on Decision Regret Scale between the provision of quality of life (QOL) information versus usual care for standard of care surgery or stereotactic body radiation therapy (SBRT) treatment. The five-point decision regret score will be converted to a 100-point score as described by others, where a higher score reflects an increased decision regret. In this schema, a decision regret score > 25 % is deemed moderate to severe regret. The dichotomized decision regret will be modeled as a function of group, time, and their interaction using a generalized estimating equations (GEE) logistic regression model with an autoregressive covariance structure. The rates of less than moderate to severe regret will be compared between groups at 6-months using a one-sided test about the appropriate contrast of model estimates.
AT 6 MONTHS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes lung cancer?

Nearly a third of patients with non-small cell lung carcinoma (NSCLC) die of causes other than [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer). The five main causes in this study were lung cancer, heart disease, smoking, pneumonia and other cancers.

Anonymous Patient Answer

What are the signs of lung cancer?

A number of signs exist that may be helpful in clinical practice. Most notably, signs that may indicate lung cancer include unexplained weight loss or loss of appetite, and unremitting cough without a specific cause. Some signs that may be suggestive of lung cancer and warrant further investigation include dyspnea, loss of appetite regardless of weight loss, fatigue, and persistent cough.

Anonymous Patient Answer

What is lung cancer?

Lung cancer is a heterogeneous disorder of different cell kinetics and differentiation with several different types, as reflected by the many classifications that have been published so far. In common usage, lung cancer usually refers to a carcinoma, which accounts for 90% of all lung malignancies. However, a benign carcinoma is also diagnosed, whereas a carcinoma in situ is a malignant tumour of preinvasive growth pattern with no invasion to the lung wall or bronchioles. In addition to these three different types, several subtypes are also recognised, the majority of which are not yet recognised by the World Health Organisation.

Anonymous Patient Answer

What are common treatments for lung cancer?

The most common treatments for lung cancer include a multidisciplinary approach that includes clinical oncologists, internists, medical oncologists, thoracic surgeons and radiologists. There is a lack of a standard approach to diagnosing lung cancer but once the disease has been diagnosed, the treatment strategy is highly dependent on the patient’s specific tumour type and the location of the primary tumour and metastases. In the case of NSCLC there is scant evidence that stereotactic body radiation therapy and chemotherapy, either alone or in combination with surgery, improves overall survival.

Anonymous Patient Answer

Can lung cancer be cured?

The lack of cure for lung cancer is associated with advances in the treatment of locally advanced disease of the lung and more effective chemotherapy. More effective radiotherapy has been shown to be associated with improved survival for locally advanced non-small cell lung cancer when compared with less effective radiotherapy.

Anonymous Patient Answer

How many people get lung cancer a year in the United States?

Lung cancers present major health problems with a high mortality worldwide. However, the incidence of lung cancer in the United States is less than other developed countries.

Anonymous Patient Answer

What is the primary cause of lung cancer?

This is a complex issue, so it will take many more studies to learn why [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is most commonly found in certain locations, in certain demographic groups, at certain ages, and why smoking increases lung cancer risk by more than 10-fold compared to never-smokers. However, it is definitely an issue that needs attention by professionals and is an understudied area of research. The lung cancer causation theories can also be classified in two broad categories: “aetiogenesis” (etiology which starts at conception), and “metastatic”, (a cause which is caused by cancer that metastasizes to a second organ within the body).

Anonymous Patient Answer

Has questionnaire administration proven to be more effective than a placebo?

We found that an acute and sustained pain questionnaire is effective in relieving cancer-related fatigue and other symptoms of cancer, and in enhancing patient compliance with the treatment and in improving patient self-efficacy.

Anonymous Patient Answer

What does questionnaire administration usually treat?

Patient-administered questionnaires, and questionnaires administered by research assistants, can produce reliable data. Such data are valuable to researchers in understanding disease-specific problems in the study population and for use in clinical practice and in population-based clinical research.

Anonymous Patient Answer

What is the survival rate for lung cancer?

The overall five-year survival rate for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) after resection has been improving year-by-year, from 45% in 1980 to about 70% in 2007. Although some cancers have decreased in recent years, other cancers, such as small cell lung cancer and non-small cell lung cancer (NSCLC), have increased. Also, in NSCLC, median survival has improved year-by-year, from 6 to 8 months. This report is one of a series issued by the US Government. Further information, including links to technical reports, figures, graphs and references, is provided in the full-text public health message, “Tobacco - The Five A's of Cigarette Smoking Safety and Treatment.

Anonymous Patient Answer

How does questionnaire administration work?

Questionnaire administration does not significantly improve the quality of responses, or reduce missing data. If used in large studies, it may introduce unnecessary cost and workload burden. There is no solid justification for using the questionnaire for this purpose.

Anonymous Patient Answer

Is questionnaire administration safe for people?

The questionnaire is feasible for older adults with chronic lung obstructive disease. As many as half of respondents would like to be re-evaluated for screening recommendations.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Lung Cancer by sharing your contact details with the study coordinator.